Literature DB >> 18559343

Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition.

Clett Erridge1, Simon Kennedy, Corinne M Spickett, David J Webb.   

Abstract

The generation of reactive oxygen species is a central feature of inflammation that results in the oxidation of host phospholipids. Oxidized phospholipids, such as 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (OxPAPC), have been shown to inhibit signaling induced by bacterial lipopeptide or lipopolysaccharide (LPS), yet the mechanisms responsible for the inhibition of Toll-like receptor (TLR) signaling by OxPAPC remain incompletely understood. Here, we examined the mechanisms by which OxPAPC inhibits TLR signaling induced by diverse ligands in macrophages, smooth muscle cells, and epithelial cells. OxPAPC inhibited tumor necrosis factor-alpha production, IkappaBalpha degradation, p38 MAPK phosphorylation, and NF-kappaB-dependent reporter activation induced by stimulants of TLR2 and TLR4 (Pam3CSK4 and LPS) but not by stimulants of other TLRs (poly(I.C), flagellin, loxoribine, single-stranded RNA, or CpG DNA) in macrophages and HEK-293 cells transfected with respective TLRs and significantly reduced inflammatory responses in mice injected subcutaneously or intraperitoneally with Pam3CSK4. Serum proteins, including CD14 and LPS-binding protein, were identified as key targets for the specificity of TLR inhibition as supplementation with excess serum or recombinant CD14 or LBP reversed TLR2 inhibition by OxPAPC, whereas serum accessory proteins or expression of membrane CD14 potentiated signaling via TLR2 and TLR4 but not other TLRs. Binding experiments and functional assays identified MD2 as a novel additional target of OxPAPC inhibition of LPS signaling. Synthetic phospholipid oxidation products 1-palmitoyl-2-(5-oxovaleryl)-sn-glycero-3-phosphocholine and 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine inhibited TLR2 signaling from approximately 30 microm. Taken together, these results suggest that oxidized phospholipid-mediated inhibition of TLR signaling occurs mainly by competitive interaction with accessory proteins that interact directly with bacterial lipids to promote signaling via TLR2 or TLR4.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559343      PMCID: PMC3259833          DOI: 10.1074/jbc.M800352200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Lateral diffusion of Toll-like receptors reveals that they are transiently confined within lipid rafts on the plasma membrane.

Authors:  Martha Triantafilou; Siegfried Morath; Alan Mackie; Thomas Hartung; Kathy Triantafilou
Journal:  J Cell Sci       Date:  2004-08-01       Impact factor: 5.285

2.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

Review 3.  Oxidized phospholipids as modulators of inflammation in atherosclerosis.

Authors:  Norbert Leitinger
Journal:  Curr Opin Lipidol       Date:  2003-10       Impact factor: 4.776

4.  Effects of methyl-beta-cyclodextrin on T lymphocytes lipid rafts with aging.

Authors:  Anis Larbi; Nadine Douziech; Abdelouahed Khalil; Gilles Dupuis; Saber Gheraïri; Karl-Philippe Guérard; Tamàs Fülöp
Journal:  Exp Gerontol       Date:  2004-04       Impact factor: 4.032

5.  A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4.

Authors:  Margaret N Kennedy; Gregory E D Mullen; Cynthia A Leifer; ChangWoo Lee; Alessandra Mazzoni; Kottarappat N Dileepan; David M Segal
Journal:  J Biol Chem       Date:  2004-06-01       Impact factor: 5.157

6.  Oxidized phospholipids in minimally modified low density lipoprotein induce apoptotic signaling via activation of acid sphingomyelinase in arterial smooth muscle cells.

Authors:  Alexandra Loidl; Eva Sevcsik; Gernot Riesenhuber; Hans-Peter Deigner; Albin Hermetter
Journal:  J Biol Chem       Date:  2003-06-19       Impact factor: 5.157

Review 7.  The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction.

Authors:  Anne F McGettrick; Luke A J O'Neill
Journal:  Mol Immunol       Date:  2004-07       Impact factor: 4.407

8.  Inhibition of LPS- and CpG DNA-induced TNF-alpha response by oxidized phospholipids.

Authors:  Zheng Ma; Jiang Li; Lijuan Yang; Ying Mu; Wen Xie; Bruce Pitt; Song Li
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-11-26       Impact factor: 5.464

9.  Oxidized phospholipids induce expression of human heme oxygenase-1 involving activation of cAMP-responsive element-binding protein.

Authors:  Gerhard Krönke; Valery N Bochkov; Joakim Huber; Florian Gruber; Stefan Blüml; Alexander Fürnkranz; Alexandra Kadl; Bernd R Binder; Norbert Leitinger
Journal:  J Biol Chem       Date:  2003-09-30       Impact factor: 5.157

10.  Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses.

Authors:  Nicolas W J Schröder; Holger Heine; Christian Alexander; Maria Manukyan; Jana Eckert; Lutz Hamann; Ulf B Göbel; Ralf R Schumann
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

View more
  90 in total

1.  Reductive metabolism increases the proinflammatory activity of aldehyde phospholipids.

Authors:  Elena Vladykovskaya; Evgeny Ozhegov; J David Hoetker; Zhengzhi Xie; Yonis Ahmed; Jill Suttles; Sanjay Srivastava; Aruni Bhatnagar; Oleg A Barski
Journal:  J Lipid Res       Date:  2011-09-27       Impact factor: 5.922

Review 2.  The role of innate immunity in atherogenesis.

Authors:  Karsten Hartvigsen; Meng-Yun Chou; Lotte F Hansen; Peter X Shaw; Sotirios Tsimikas; Christoph J Binder; Joseph L Witztum
Journal:  J Lipid Res       Date:  2008-12-22       Impact factor: 5.922

3.  Apolipoprotein(a) inhibits lipopolysaccharide-induced IL-6 secretion in human astrocytoma cell line by interfering with lipopolysaccharide signaling.

Authors:  Guglielmina Chimienti; Anna Mezzapesa; Grazia M Liuzzi; Tiziana Latronico; Gabriella Pepe
Journal:  Inflamm Res       Date:  2010-11-02       Impact factor: 4.575

4.  Penehyclidine ameliorates acute lung injury by inhibiting Toll-like receptor 2/4 expression and nuclear factor-κB activation.

Authors:  N A Wang; Yue Su; Xiang-Ming Che; Hui Zheng; Zhi-Guo Shi
Journal:  Exp Ther Med       Date:  2016-03-11       Impact factor: 2.447

5.  Preferential hydrolysis of truncated oxidized glycerophospholipids by lysosomal phospholipase A2.

Authors:  Akira Abe; Miki Hiraoka; Hiroshi Ohguro; John J Tesmer; James A Shayman
Journal:  J Lipid Res       Date:  2016-12-19       Impact factor: 5.922

6.  VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis.

Authors:  I Mendel; E Feige; N Yacov; Y Salem; I Levi; O Propheta-Meiran; A Shoham; E Ishai; J George; D Harats; E Breitbart
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

7.  Saturated long-chain fatty acids activate inflammatory signaling in astrocytes.

Authors:  Sunita Gupta; Alecia G Knight; Shruti Gupta; Jeffrey N Keller; Annadora J Bruce-Keller
Journal:  J Neurochem       Date:  2012-02-06       Impact factor: 5.372

8.  Toll-like receptors participate in Naegleria fowleri recognition.

Authors:  Moisés Martínez-Castillo; Leopoldo Santos-Argumedo; José Manuel Galván-Moroyoqui; Jesús Serrano-Luna; Mineko Shibayama
Journal:  Parasitol Res       Date:  2017-11-11       Impact factor: 2.289

9.  The role of oxidized phospholipids in atherosclerosis.

Authors:  Judith A Berliner; Norbert Leitinger; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2008-12-04       Impact factor: 5.922

10.  Suppression of Toll-like receptor 4 activation by endogenous oxidized phosphatidylcholine, KOdiA-PC by inhibiting LPS binding to MD2.

Authors:  Min Jin Kim; Na Young Choi; Jung Eun Koo; So Young Kim; Sun Myung Joung; Eunshil Jeong; Joo Young Lee
Journal:  Inflamm Res       Date:  2013-03-09       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.